- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, March 1, 2024
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
An article on mHealthIntelligence referenced a study published in the February 2024 issue of The American Journal of Managed Care® (AJMC®). The study, “Scaling Care Coordination Through Digital Engagement: Stepped-Wedge Trial Assessing Readmissions,” found that a patient postdischarge digital engagement program was able to offer patients in resource-limited areas expanded access to care while also having no effect on readmissions.
An article from POZ referenced an article published on AJMC.com, the website of AJMC. The article, “Vaccination for Hepatitis A Low in People Living With HIV,” summarized a study that found that lower hepatitis A virus vaccination uptake was common in patients with substance use disorders, young patients, and patients who were immunocompromised if they had HIV.
An article from BNN Breaking referenced an article published on AJMC.com. The article, “Not So Rare: 300 Million People Worldwide Affected by Rare Diseases,” discussed new research that found about 4% of the total population of the world were affected by a rare disease of some kind.
The written interview titled, “Dr Leesha Ellis-Cox Confronts Racial Bias, Diagnosis Disparities in Mental Health Care,” was referenced in Nation World News. The written interview featured questions answered by Ellis-Cox on reasons for less mental health diagnoses in Black Americans and why underrepresentation of Black Americans in the health care system poses a challenge to other Black Americans with a mental health diagnosis.
Health Equity & Access Weekly Roundup: November 23, 2024
November 23rd 2024Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.
Read More
FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy
November 22nd 2024The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.
Read More
